Inventure’s Post

Today we're proud to announce we've backed MONCYTE Health to enable a new era of personalized treatment strategies for high cholesterol. 1.5 billion people are at risk of strokes and heart attacks due to high cholesterol, and no treatment plan is a one-size-fits-all. Moncycte's technology can quantify individual differences in cellular lipid uptake and storage, assisting physicians to prescribe the proper treatment, and pharmaceutical companies to study how novel lipid-lowering drugs influence the cellular processes contributing to cardiovascular risk. Congratulations to Tamara, Simon, and the entire MONCYTE team!

Great session this morning with our People and Operations lead, Therese Öberg!

In our latest newsletter, we ran through the headlines of a busy summer: Canatu going public, Steep and toddle moving from pre-seed to seed, and a few exciting new portfolio companies including Biomatter, Valo, and Livv Health. Read all that and more, here:

Cooking up the next big thing? Catch Linus, Lauri, and Kevin this week at TechBBQ!

We're excited to announce our investment in Biomatter, leading their €6.5M Seed round alongside UVC Partners. There's huge potential in this technology. Biomatter is revolutionizing enzyme design with AI, creating custom designed enzymes from scratch that could transform industries from pharma to agriculture. Why are we so excited? Kevin Lösch writes that now we're not limited to tweaking the enzymes we discover in nature- the only limit is our creativity. We see this as transformative for enzyme design as CRISPR was for gene editing. Read more about why we invested in Laurynas, Irmantas, Donatas, Vykintas, and the biomatter team, and the potential impact of this game-changing technology here: